Phase 2 Clinical Trial of Bermekimab Shows Potential New Standard of Care for Treatment of Hidradenitis Suppurativa, Including Significant Pain Reduction without Antibiotics
AUSTIN, Texas, March 05, 2019 (GLOBE NEWSWIRE) — XBiotech (NASDAQ: XBIT) today released findings for its Phase 2 clinical study …